June 2019

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)’s share price shot up 6.6% during trading on Friday . The company traded as high as $13.61 and last traded at $13.55. 4,039,043 shares traded hands during trading, an increase of 107% from the average session volume of 1,950,577 shares. The stock had previously closed at $12.71. A number of brokerages […]

Intercept Pharmaceuticals (NASDAQ: ICPT) and CV Sciences (NASDAQOTH: CVSI) have practically nothing in common. Intercept is a biotech focused on developing and marketing liver disease drugs, while CV Sciences is a leader in the hemp cannabidiol (CBD) market.  There are two similarities between Intercept and CV Sciences, though. Both stocks appear to have great long-term […]

Mark Roth, Ph.D., and colleagues in the Fred Hutch Basic Sciences Division published their findings online in Critical Care Medicine. “We found that administration of selenide after the heart has been deprived of blood flow and before blood flow is restored significantly protects the heart tissue in a mouse model of acute myocardial infarction and […]

Editorial: Sonja Sherritze, EditorAdvertising: Maureen Dwyer Liberti, Vice President, Group PublisherGreg Pessagno, National Account ManagerAmy Birnbach, National Account ManagerProduction: Dawn Flook, Director of Production ServicesCirculation: Jackie Ott, Circulation ManagerWebmaster: Webmaster … read more at: https://www.ptcommunity.com/news/20190214/oncology-drug-pv-10-gets-orphan-drug-status-ocular-melanoma

Zynerba Pharmaceuticals (NASDAQ:ZYNE) has been assigned a $18.00 target price by research analysts at Canaccord Genuity in a research report issued on Friday, Stock Target Advisor reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity’s price objective indicates a potential upside of 32.84% from the stock’s previous close. Several other equities […]

Zynerba Pharmaceuticals (NASDAQ:ZYNE) has been assigned a $18.00 target price by research analysts at Canaccord Genuity in a research report issued on Friday, Stock Target Advisor reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity’s price objective indicates a potential upside of 32.84% from the stock’s previous close. Several other equities […]

Kazia Therapeutics Limited (NASDAQ:KZIA) and Intec Pharma Ltd. (NASDAQ:NTEC) compete against each other in the Biotechnology sector. We will contrast them and contrast their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation. Earnings Valuation Demonstrates Kazia Therapeutics Limited and Intec Pharma Ltd. earnings per share (EPS), top-line revenue and valuation. Profitability Table 2 […]

Kazia Therapeutics Limited (NASDAQ:KZIA) and Intec Pharma Ltd. (NASDAQ:NTEC) compete against each other in the Biotechnology sector. We will contrast them and contrast their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation. Earnings Valuation Demonstrates Kazia Therapeutics Limited and Intec Pharma Ltd. earnings per share (EPS), top-line revenue and valuation. Profitability Table 2 […]

An herbal tincture is a concentrated liquid form of one or more herbs. To make a tincture, a person must soak parts of an herb for several weeks in alcohol or vinegar. The soaking process extracts the active components of the herb or herbs. Alcohol is often the liquid of choice, as it can extract […]